Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on monoclonal antibody therapies for serious viral infectious diseases, beginning with SARS-CoV-2. The Invivyd news feed on Stock Titan highlights company announcements about clinical development, regulatory milestones, commercial performance, financing activities, and pipeline expansion.
Recent Invivyd news has featured updates on PEMGARDA (pemivibart), the company’s investigational monoclonal antibody authorized under a U.S. FDA emergency use authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adolescents. The company reports quarterly PEMGARDA net product revenue and discusses uptake among healthcare providers caring for immunocompromised patients.
Investors also see frequent coverage of VYD2311, Invivyd’s vaccine-alternative monoclonal antibody candidate for COVID-19. News items describe FDA Fast Track designation, U.S. IND clearance, and the design of the Phase 3 DECLARATION trial within the broader REVOLUTION clinical program. Articles outline trial endpoints, intramuscular dosing regimens, and plans for pivotal data to support a potential Biologics License Application.
Beyond COVID-19, Invivyd’s news flow includes pipeline developments such as the selection of VBY329, a monoclonal antibody candidate for prevention of RSV infections in neonates, infants, and children, and discovery efforts targeting measles and other infectious diseases. Corporate news covers public offerings of common stock and pre-funded warrants, participation in healthcare conferences, and formation of the SPEAR Study Group to evaluate monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
By following the IVVD news page, readers can review Invivyd’s official press releases and related updates in one place, including earnings announcements, clinical trial progress, regulatory designations, and capital-raising transactions.
Invivyd (Nasdaq: IVVD) reported full-year 2025 net product revenue for PEMGARDA of $53.4M and Q4 2025 PEMGARDA revenue of $17.2M (Q4 YoY +25%). Cash and cash equivalents were $226.7M at year-end after >$200M raised in 2H 2025. DECLARATION Phase 3 enrollment is complete; top-line VYD2311 data expected mid-2026. FDA granted Fast Track for VYD2311 in Dec 2025. R&D expense fell to $38.3M and net loss narrowed to $52.5M for 2025.
Invivyd (Nasdaq: IVVD) appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer effective March 5, 2026. Dr. Mina brings expertise in infectious disease epidemiology, immunology, and clinical strategy, with more than 100 scientific publications and 10,000 citations.
His background includes academic posts at Harvard and leadership roles in diagnostics and digital health, and he will support Invivyd’s monoclonal antibody prevention and treatment pipeline.
Invivyd (Nasdaq: IVVD) will host a conference call on March 5, 2026 at 8:30 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a corporate update.
Interested parties can access a live webcast and analysts can join the Q&A via designated links; a recording will be posted to the company investor relations website shortly after the event.
Invivyd (Nasdaq: IVVD) granted inducement stock options to four newly hired non-executive employees on March 1, 2026, totaling 192,000 shares under the 2026 Inducement Plan.
The options carry a $1.69 exercise price (closing price Feb 27, 2026), vest over four years (25% after one year, then monthly), have a 10-year term, and were granted under Nasdaq Listing Rule 5635(c)(4).
Invivyd (Nasdaq: IVVD) published a peer-reviewed correlate-of-protection model that links serum monoclonal antibody levels to clinical protection against symptomatic COVID-19 across multiple Omicron-era variants.
The model, using CANOPY Phase 3 data for pemivibart, aligns with observed outcomes and predicts meaningful protection even at low antibody concentrations, supporting variant-agnostic assessment of COVID mAbs.
Invivyd (Nasdaq: IVVD) said it is aligned with the U.S. FDA on LIBERTY, a Phase 3 trial to compare safety and immunology of its monoclonal antibody candidate VYD2311 versus mRNA COVID vaccines and to study co-administration.
The FDA requested specific monitoring of myocarditis/pericarditis adverse events of special interest for LIBERTY; DECLARATION Phase 3 topline data remain expected mid-2026 with ~1,770 total participants.
Invivyd (Nasdaq: IVVD) announced a national multimedia education partnership with champion skier Lindsey Vonn to raise public awareness about antibodies and infectious disease prevention. The campaign is planned to launch in early Spring 2026, with Vonn serving as the public spokesperson to connect antibody science to health and wellness. Vonn, a decorated Olympian and 84-time World Cup winner who returned to competition in 2024 and qualified in December for the Milan Cortina 2026 Olympic Winter Games, will help translate antibody concepts into accessible guidance for the American public.
Invivyd (Nasdaq: IVVD) and the SPEAR Study Group plan a Phase 2 trial of monoclonal antibody VYD2311 to evaluate safety, translational biology, and exploratory clinical efficacy in people with Long COVID or COVID vaccine injury, with initiation expected mid-2026. The randomized, double-blind, placebo-controlled design will test multiple long-term high doses of VYD2311 and enroll participants who demonstrate persistent infection or antigenemia where technologically detectable.
VYD2311 has shown in vitro antiviral activity across all clinically recorded SARS-CoV-2 variants tested since the Wuhan strain. Further trial details and clinicaltrials.gov registration are expected to be posted in coming months.
Invivyd (NASDAQ: IVVD) reported preliminary Q4 2025 PEMGARDA net product revenue of $17.2M, up 25% YoY and 31% QoQ. Ending cash and cash equivalents are expected to be $226.7M after >$200M raised in 2H 2025. The company initiated the DECLARATION Phase 3 randomized trial of VYD2311 (single IM dose and monthly arms; total expected enrollment 1,770) with topline data expected mid-2026, and VYD2311 received FDA Fast Track designation in Dec 2025. Invivyd nominated RSV candidate VBY329 for preclinical development (higher potency vs nirsevimab/clesrovimab) and targets a preclinical measles mAb select in 1H 2026. Further details to accompany the Form 10-K and regular filings.
Invivyd (Nasdaq: IVVD) announced the U.S. FDA granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody to prevent COVID in individuals with underlying risk factors for severe disease. Fast Track can enable priority review and rolling BLA submission if criteria are met.
Invivyd is conducting DECLARATION, a Phase 3, randomized, triple-blind, placebo-controlled, BLA‑enabling trial of VYD2311 with planned total enrollment of 1,770 participants. Participants receive a single or monthly intramuscular dose versus placebo. Top-line data are expected mid-2026.